Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label Trial of Trastuzumab Deruxtecan (Enhertu, DS-8210) in HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2

NCT07126561 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT07126561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07126561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label Trial of Trastuzumab Deruxtecan (Enhertu, DS-8210) in HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 1, 2028
Enrollment
43 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive newly diagnosed metastatic esophageal, gastric, gej cancer patients with an ecog performance status of 2